A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators

Author:

Garashi Hamza Y.ORCID,Steinke Douglas T.,Schafheutle Ellen I.

Abstract

Abstract Background In the context of the growth of pharmacovigilance (PV) among developing countries, this systematic review aims to synthesise current research evaluating developing countries’ PV systems’ performance. Methods EMBASE, MEDLINE, CINAHL Plus and Web of Science were searched for peer-reviewed studies published in English between 2012 and 2021. Reference lists of included studies were screened. Included studies were quality assessed using Hawker et al.'s nine-item checklist; data were extracted using the WHO PV indicators checklist. Scores were assigned to each group of indicators and used to compare countries’ PV performance. Results Twenty-one unique studies from 51 countries were included. Of a total possible quality score of 36, most studies were rated medium (n = 7 studies) or high (n = 14 studies). Studies obtained an average score of 17.2 out of a possible 63 of the WHO PV indicators. PV system performance in all 51 countries was low (14.86/63; range: 0–26). Higher average scores were obtained in the ‘Core’ (9.27/27) compared to ‘Complementary’ (5.59/36) indicators. Overall performance for ‘Process’ and ‘Outcome’ indicators was lower than that of ‘Structural’. Conclusion This first systematic review of studies evaluating PV performance in developing countries provides an in-depth understanding of factors affecting PV system performance.

Funder

Kuwait Ministry of Health

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Reference81 articles.

1. Segura-Bedmar I, Martinez P. Special issue on mining the pharmacovigilance literature. J Biomed Inform. 2014;49:1–2.

2. Jeetu G, Anusha G. Pharmacovigilance: a worldwide master key for drug safety monitoring. J Young Pharm. 2010;2(3):315–20.

3. World Health Organization (WHO). The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products Geneva: World Health Organization; 2002. https://apps.who.int/iris/handle/10665/42493. Accessed 28 Feb 2022

4. World Health Organization (WHO). Clinical trials Geneva: World Health Organization; 2022. https://www.who.int/health-topics/clinical-trials#tab=tab_1. Accessed 1 March 2022

5. NIH National Institute on Aging. What Are Clinical Trials and Studies? Baltimore, MD.: National Institutes of Health (NIH) National Institute on Aging (NIA); 2020. https://www.nia.nih.gov/health/what-are-clinical-trials-and-studies. Accessed 1 March 2022

Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Safety assessment of Yasmin: Real-world adverse event analysis using the FAERS database;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-10

2. Reimagining the ADR Alert Card: a novel approach to recurrence prevention in low-cost settings for adverse drug reactions;European Journal of Hospital Pharmacy;2024-09-03

3. Mitigating Challenges in Pharmacovigilance;Pharmacovigilance - Facts, Challenges, Limitations and Opportunity [Working Title];2024-07-31

4. Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges—A Narrative Review;Pharmaceuticals;2024-06-19

5. Global trends in pharmacovigilance-related events: a 30-year analysis from the 2019 global burden of disease study;International Journal of Clinical Pharmacy;2024-05-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3